Track record · closed signal

Halozyme Therapeutics Inc (HALO) — closed signal from June 24, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on September 22, 2026 — +63.7% at the close.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted

$67.00 – $71.00Entry zone — fair-value band

$70.31Published — price the day we called it

$80.15Target — the price the thesis aimed for

$115.18Peak — highest point inside the window, not a realized return

$115.13Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 12 days.

At window close

+63.7%

realized, from the publication price to the last close inside the window

Peak gain

+63.8%

peak, from the publication price — not a realized return

S&P 500, same window

+5.7%

SPY over the identical days, dividend-adjusted

Window close

$115.13

last close inside the window, ended September 22, 2026

Peak price

$115.18

peak on September 22, 2026 — not a realized return

Days to target

The thesis — published June 24, 2026

Predicted growth

+14%

over the measurement window

Target price

$80.15

the price the thesis aimed for

Entry zone

$67.00 – $71.00

the fair-value band we waited for

Price at publication

$70.31

published June 24, 2026

Confidence

66%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Halozyme's recent policy and partner trial news reduce a big uncertainty and show its delivery tech can work with other drugs. The company looks reasonably valued for expected growth, but debt, insiders selling, and some missed earnings keep confidence cautious. Short-term upside may follow more positive news.

Primary drivers

Medicare rule change reduces future royalty uncertainty
Partner trial results make the delivery tech more credible
Company growth looks attractive relative to current price
Debt levels and uneven earnings limit conviction

How it played out

HALO: target reached in 12 days, peak gain was 63.8%

Lyra published HALO at $70.31 with expected growth of 14% and a target of $80.15. The thesis pointed to lower royalty uncertainty from a Medicare rule change, encouraging partner trial results, and growth that looked attractive relative to the price. Debt and uneven earnings limited conviction.

The shares reached the target in 12 days. They later peaked at $115.18 on September 22, a gain of 63.8%, and ended the window at $115.13. The price cleared the target and held near its peak through the close. The thesis played out and exceeded its stated price objective.

What happened during the window

On July 20, 2026, Halozyme announced a global collaboration and license agreement with Incyte involving its drug delivery technology. On August 6, 2026, the company reported second-quarter results and raised its full-year financial guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals